SILEXION THERAPEUTICS CORP (SLXN) Stock Price, Quote, News and Overview
NASDAQ:SLXN - Nasdaq - Common Stock
SLXN Quote and Key Statistics
SILEXION THERAPEUTICS CORP
NASDAQ:SLXN (1/22/2025, 10:47:08 AM)
0.7599
-0.01 (-1.31%)
SLXN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.85% | ||
| ROE | -20.8% | ||
| Debt/Equity | 0 |
SLXN Performance and Technical Analysis
SLXN Ownership and Analysts
SLXN Latest News and Analysis
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Top movers in Thursday's session
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Gapping stocks in Thursday's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
What's going on in today's pre-market session
Stay updated with the stocks that are on the move in Thursday's pre-market session.
Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials planned for 2026.
About SLXN
Company Profile
Silexion Therapeutics Corp is a IL-based company operating in Biotechnology industry. Silexion Therapeutics Corp is an oncology-focused biotechnology company. The firm is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
Company Info
SILEXION THERAPEUTICS CORP
12 Abba Hillel Road
Ramat Gan NEW YORK IL
Employees: 0
Company Website: https://www.moringaac.com/
Investor Relations: http://www.moringaac.com/sec-filing
Phone: 97286286005
SLXN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.8 | 300.15B | ||
| AMGN | AMGEN INC | 14.23 | 147.04B | ||
| GILD | GILEAD SCIENCES INC | 20.77 | 114.66B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 841.59 | 110.53B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.25 | 76.15B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.53B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.20B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.48B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.07B | ||
| NTRA | NATERA INC | N/A | 22.49B | ||
| BIIB | BIOGEN INC | 8.71 | 20.72B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.82B |